Clinical Course of the Benign Prostate Hyplasia Patients during the Intermittent Use of 5-Alpha Reductase Inhibitors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: 5-Alpha reductase inhibitors (5ARI), inhibit the conversion of testosterone to dihydrotestosterone, which is essential in prostate hyperplasia, and decreases the prostate volume directly. On the other hand, 5ARI have a range of side effects, such as sexual dysfunction. After the discontinuation of 5ARI, prostate regrowth occurs rapidly until it reaches the baseline size. This study examined the effects of 5ARI when used intermittently.Materials and Methods: Between March 2009 and May 2017, patients who visited one physician’s outpatient clinic and were diagnosed with BPH underwent transrectal ultrasonography. The selected patients began to take 5ARI until the prostate size decreased at least 10% of the baseline (the first medication). After confirming adequate prostate shrinkage, the patients stopped medication until prostate regrowth reached 50% of the decreased size. After regrowth, they restarted medication for one year (second medication). The prostate size, serum prostate specific antigen (PSA) levels, international prostate symptom score (IPSS) scores, and maximum flow rate (Qmax) in uroflowmetry were collected after the first and second medication and compared using paired t-tests.Results: Sixty patients with a mean age of 65.1 years were included in the study. The prostate size and serum PSA level increased after the second medication compared to the first, and the prostate reduction and Qmax in uroflowmetry decreased significantly. On the other hand, the symptoms felt by the patients surveyed by the IPSS scores showed no significant difference.Conclusions: 5ARI appear to be less effective in reducing the prostate volume and improving uroflowmetry after discontinuation.
Abstract
Purpose: 5-Alpha reductase inhibitors (5ARI), inhibit the conversion of testosterone to dihydrotestosterone, which is essential in prostate hyperplasia, and decreases the prostate volume directly. On the other hand, 5ARI have a range of side effects, such as sexual dysfunction. After the discontinuation of 5ARI, prostate regrowth occurs rapidly until it reaches the baseline size. This study examined the effects of 5ARI when used intermittently.Materials and Methods: Between March 2009 and May 2017, patients who visited one physician’s outpatient clinic and were diagnosed with BPH underwent transrectal ultrasonography. The selected patients began to take 5ARI until the prostate size decreased at least 10% of the baseline (the first medication). After confirming adequate prostate shrinkage, the patients stopped medication until prostate regrowth reached 50% of the decreased size. After regrowth, they restarted medication for one year (second medication). The prostate size, serum prostate specific antigen (PSA) levels, international prostate symptom score (IPSS) scores, and maximum flow rate (Qmax) in uroflowmetry were collected after the first and second medication and compared using paired t-tests.Results: Sixty patients with a mean age of 65.1 years were included in the study. The prostate size and serum PSA level increased after the second medication compared to the first, and the prostate reduction and Qmax in uroflowmetry decreased significantly. On the other hand, the symptoms felt by the patients surveyed by the IPSS scores showed no significant difference.Conclusions: 5ARI appear to be less effective in reducing the prostate volume and improving uroflowmetry after discontinuation.
참고문헌 (21)
- Boyle P, "5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery", Eur Urol, 45, pp.620~626 (2004)[DOI]
- Jacobsen SJ, "Natural history of prostatism : risk factors for acute urinary retention", J Urol, 158, pp.481~487 (1997)
- Oelke M, "Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)" (2013), European Association of Urology
- Marks LS, "The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors : a review and clinical recommendations", J Urol, 176, pp.868~874 (2006)
- Seftel AD, "Coexisting lower urinary tract symptoms and erectile dysfunction : a systematic review of epidemiological data", Int J Clin Pract, 67, pp.32~45 (2013)
- 김원옥, "Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia", Investigative and Clinical Urology, 55(1), pp.52~56 (2014), 대한비뇨의학회
- Kwibok Choi, "Patient’s Factors Correlated with Prostate Volume Recovery after 5 Alpha Reductase Inhibitor Discontinuation", Urogenital Tract Infection, 13(3), pp.79~83 (2018), 대한요로생식기감염학회[DOI]
- Girman CJ., "Population-based studies of the epidemiology of benign prostatic hyperplasia", Br J Urol, 82(Suppl 1), pp.34~43 (1998)
- Emberton M, "Benign prostatic hyperplasia : a progressive disease of aging men", Urology, 61, pp.267~273 (2003)
- 신유섭, "Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial", Investigative and Clinical Urology, 58(2), pp.98~102 (2017), 대한비뇨의학회[DOI]
- Kirby RS, "Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial", Urology, 61, pp.119~126 (2003)
- Djavan B, "A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction", Eur Urol, 36, pp.1~13 (1999)
- Kaplan SA, "Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate : data from the MTOPS trial", J Urol, 185, pp.1369~1373 (2011)
- Andersen JT, "Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia", Urology, 49, pp.839~845 (1997)
- Madersbacher S, "The long-term outcome of medical therapy for BPH", Eur Urol, 51, pp.1522~1533 (2007)
- Nickel JC, "Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two Year Study", CMAJ, 155, pp.1251~1259 (1996)
- Hudson PB, "Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group", Urology, 53, pp.690~695 (1999)
- Corona G, "Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia : a comprehensive review and meta-analysis", Andrology, 5, pp.671~678 (2017)
- Trost L, "Side effects of 5-alpha reductase inhibitors : a comprehensive review", Sex Med Rev, 1, pp.24~41 (2013)
- Stoner E., "The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group", J Urol, 147, pp.1298~1302 (1992)
- Jeong YB, "Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH : a prospective study", Urology, 73, pp.802~806 (2009)